Journal
MOVEMENT DISORDERS
Volume 35, Issue 7, Pages 1233-1238Publisher
WILEY
DOI: 10.1002/mds.28026
Keywords
biomarker; longitudinal study; neurofilament light chain (NfL); Parkinson's disease (PD); premanifest disease; prodromal symptoms; serum; single molecule array (Simoa) technique
Categories
Funding
- BioPharma initiative Neuroallianz (project D13 B) of the German Federal Ministry for Education and Research [16GW0066K, 16GW0067]
- Horizon 2020 research and innovation program [779257 Solve-RD]
- National Ataxia Foundation
- Wilhelm Vaillant Stiftung
- UCB Pharma GmbH (Monheim am Rhein, Germany)
Ask authors/readers for more resources
Background and Objectives With disease-modifying treatment strategies on the horizon, stratification of individual patients at the earliest stages of Parkinson's disease (PD) is key-ideally already at clinical disease onset. Blood levels of neurofilament light chain (NfL) provide an easily accessible fluid biomarker that might allow capturing the conversion from prodromal to manifest PD. Methods We assessed longitudinal serum NfL levels in subjects converting from prodromal to manifest sporadic PD (converters), at-risk subjects, and matched controls (72 participants with approximate to 4 visits), using single-molecule array (Simoa) technique. Results While NfL levels were not increased at the prodromal stage, subjects converting to the manifest motor stage showed a significant intraindividual acceleration of the age-dependent increase of NfL levels. Conclusions The temporal dynamics of intraindividual NfL blood levels might mark the conversion to clinically manifest PD, providing a potential stratification biomarker for individual disease onset in the advent of precision medicine for PD. (c) 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available